Abstract
The Zika virus (ZIKV) is a vector-borne flavivirus that has been detected in 87 countries worldwide. Outbreaks of ZIKV infection have been reported from various places around the world and the disease has been declared a public health emergency of international concern. ZIKV has two modes of transmission: vector and non-vector. The ability of ZIKV to vertically transmit in its competent vectors, such as Aedes aegypti and Aedes albopictus, helps it to cope with adverse conditions, and this could be the reason for the major outbreaks that occur from time to time. ZIKV outbreaks are a global threat and, therefore, there is a need for safe and effective drugs and vaccines to fight the virus. In more than 80% of cases, ZIKV infection is asymptomatic and leads to complications, such as microcephaly in newborns and Guillain–Barré syndrome (GBS) in adults. Drugs such as sofosbuvir, chloroquine, and suramin have been found to be effective against ZIKV infections, but further evaluation of their safety in pregnant women is needed. Although temoporfin can be given to pregnant women, it needs to be tested further for side effects. Many vaccine types based on protein, vector, DNA, and mRNA have been formulated. Some vaccines, such as mRNA-1325 and VRC-ZKADNA090-00-VP, have reached Phase II clinical trials. Some new techniques should be used for formulating and testing the efficacy of vaccines. Although there have been no recent outbreaks of ZIKV infection, several studies have shown continuous circulation of ZIKV in mosquito vectors, and there is a risk of re-emergence of ZIKV in the near future. Therefore, vaccines and drugs for ZIKV should be tested further, and safe and effective therapeutic techniques should be licensed for use during outbreaks.
Introduction
The Zika virus (ZIKA) has affected about 87 countries worldwide since 2019, especially countries in tropical and subtropical regions (1). ZIKA is a Flavivirus, having a positive-sense, single-stranded RNA encoding for three structural proteins [i.e., precursor membrane protein (prM), capsid protein (C), and envelope protein (E)] and seven non-structural proteins (i.e., NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (2). In 1950, the first case of human infection with ZIKA was reported in Africa. In 2016, the WHO declared ZIKA infection a public health emergency of international concern (3). ZIKV is found in several WHO regions (i.e., the African Region, Region of the Americas, South-East Asia Region, and the Western Pacific Region) (4). Recently, in India in 2021, a total of 150 cases of ZIKV infection were reported. Most patients were asymptomatic or had a mild fever (5). Figure 1 shows the regions at risk of ZIKV infection.
Figure 1
Transmission of ZIKV
The Zika virus mainly spreads through an Aedes mosquito bite, but can also spread by non-vector transmission, for example by congenital transmission, blood transfusion, organ transplantation, sexual transmission, and vertical transmission (4). The vertical transmission capacity of ZIKV has been studied in Aedes mosquitoes, and vertical transmission has been found to help ZIKV to cope with harsh conditions (7). ZIKV is an arbovirus that is transmitted by two cycles: a sylvatic cycle involving transmission between non-human primates and arboreal insects in forests, and an urban cycle between humans and urban mosquitoes (8). The ZIKV transmission cycle is shown in Figure 2.
Figure 2
Vector competency for ZIKV
In Asian and African mosquitos, Ae. aegypti, Ae. albopictus, Ae. vexans, Ae. (Rampamyia) notoscriptus, Ae. (Ochlerotatus) camptorhynchus, Ae. vittatus, Ae. luteocephalus, and Culex quinquefasciatus act as potential vectors (9, 10). Anopheles gambiae, A. stephensi, and Cx pipiens have also been shown to be probable vectors (11). Ae. (Stegomyia) hensilli and Ae. (Stegomyia) polynesiensis were found to be probable vectors during the ZIKV outbreak in Yap Island and French Polynesia (12). Vectorial capacity (i.e., vector-borne transmission ability) is affected by the ecological traits and abundance of vectors, and poor vectors with limited vector competence can lead to outbreaks worldwide (10, 13). Del Carpio et al. (2018) revealed that in Mexico a variety of species of Culicidae were present. In Mexico, Ae. Aegypti and Ae. albopictus, A. species such as A. albimanus and A. pseudopunctipennis, and Culex family members, such as Cx perfuscus, Cx pipens, and Cx quinquefasciatus, act as potential vectors during outbreaks. However, some mosquito species endemic to Mexico, for example, Ae. sumidero, Ae. tehuantepec, Ae. guerrero, Ae. ramirezi, Ae. laguna, Ae. cozumelensis, Cx jalisco, Cx sandrae, Cx schicki, Cx arizonensis, and A. aztecus, could act as a vector in the absence of potential vectors. In America, the Culicidae family is highly diversified and competes with Aedes species for being a potential vector to transmit ZIKV (14). A comprehensive assessment of vector competency in Brazil concluded that Aedes species can cause a pandemic in the absence of arboviral-specific vectors, such as Ae. Aegypti, while other species like Ae. albopictus or Ae. japonicus can act as potential vectors for arboviruses (15). The distribution of probable vectors is shown in Figure 3.
Figure 3
Symptoms of ZIKV infection
The incubation period of ZIKV is approximately 3–14 days. The majority of people, ≈80%, do not show any symptoms of infection. Symptoms that are observed in 20%–25% of ZIKV patients with an acute infection include joint pain, conjunctivitis, malaise, muscle pain, headache, fever, and rash, as shown in Figure 4. These symptoms generally last for 2–7 days (1).
Figure 4
Complications of ZIKV disease
ZIKV infection during pregnancy can result in fetal loss, stillbirth, and preterm birth. In newborns, ZIKV can cause congenital abnormalities such as microcephaly (16). ZIKV infection also triggers myelitis, Guillain–Barré syndrome (GBS), and neuropathy in adults and older children (1). The complications, such as microcephaly, are shown in Figures 5, 6.
Figure 5
Figure 6
Acute ZIKV infection is self-limiting, and patients recover, but the matter of serious concern is neonatal complications, which are associated with chronic ZIKV infection. In 2015, during a ZIKV outbreak in Brazil, the number of cases of newborns with microcephaly increased (17). Complications such as optic neuropathy, glaucoma, lissencephaly, microcephaly, and ventriculomegaly are also associated with ZIKV infection, as ZIKV mRNA was observed in the amniotic fluid of pregnant women (18). ZIKV infection in pregnant women has been shown to be harmful to fetuses. In the first and second trimesters of pregnancy, ZIKV infection can have severe effects, such as spontaneous abortion, congenital abnormalities, and fetal death, or necessitate therapeutic abortion due to congenital malformation. Congenital abnormalities such as microcephaly, hydrocephalus, hypoplasia, hypertonicity, cerebellar calcification, and seizures related to the neurological system, osteoskeletal system abnormalities, such as arthrogryposis and clubfoot, and optic system abnormalities, such as ophthalmic changes in the posterior and anterior segments, and abnormal visual functions, were observed in neonates with the help of image tests (19). An acute infection of ZIKV may lead to GBS. GBS is an autoimmune condition in which gradual muscle weakness, reduced nerve function, and paralysis are observed as myelinated neural cells are attacked by cell-mediated immunity (20, 21). In French Polynesia, during a ZIKV outbreak in 2013–14, cases of GBS increased 20-fold, and a close relationship was seen between the manifestation of ZIKV and GBS (20). In other studies, it has been reported that the prevalence of GBS with ZIKV is 42% and 24% in Brazil and America, respectively. The variations in prevalence, which have been reported, may be due to the reduced incidence as a result of the low virulence and pathogenicity of the virus. Other GBS-causing agents include a species of Campylobacter and various arboviruses related to ZIKV (22, 23).
Mechanism of ZIKV neuropathogenesis
ZIKV infection leads to neuropathogenesis through various mechanisms, neuronal apoptosis of the immune response, an inflammatory response, and cell-cycle dysregulation (24). In many studies, it has been found that, during vertical transfer from an infected mother to a developing fetus, ZIKV can successfully infect human neural progenitor cells (hNPCs) (25). During the first trimester of pregnancy, hNPCs generate brain organoids and neurospheres for fetal brain development, but either hNPCs infected with ZIKV show a cytopathic effect and die, or the cytopathic effect is reduced by virus replication, leading to brain abnormalities such as microcephaly and restriction of fetal brain development (24, 26). It has been observed previously that cells with highly expressed Axl receptor tyrosine kinase (AXL) receptors are more susceptible to ZIKV infection (27). The AXL receptor mediates the ZIKV infection to keratinocytes and fibroblasts. The various cellular receptors known to be involved in ZIKV neuropathogenesis are dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), phosphatidylserine receptor proteins, such as T-cell immunoglobulin mucin-1 (TIM-1), TIM-4, AXL, and tyrosine–protein kinase receptor 3 (TYRO3), and heat shock proteins (HSPs), glucose-regulating protein 78 (GRP78/BiP), and a cluster of differentiation (CD) 14-associated molecules (28–30). In addition, ZIKV interacts with toll-like receptor 3 (TLR3) and induces an interferon response. ZIKV has to overcome the innate immune barrier by degrading the signal transducer and activator of transcription 2 (STAT2) (2). It has been found that silencing of the AXL gene up-regulates type I interferon signaling, indicating that AXL helps in increasing ZIKV infection by down-regulating type I interferon signaling (31). Recent studies have revealed that ZIKV infection is not solely dependent on AXL, limiting the possibility of developing any therapeutics (32). The vertical transmission and neuropathogenesis mechanism of ZIKV infection in humans is shown in Figure 7.
Figure 7
Aedes mosquitoes are the probable vector for ZIKV transmission. Figure 7A shows how ZIKV can infect dermal fibroblasts and epidermal keratinocytes, which might then spread the virus to dermal dendritic cells (also known as Langerhans cells) and aid the spread of ZIKV. Figure 7B shows how infection of cytotrophoblasts or transmigration of infected primary human placental macrophages (Hofbauer cells) may result in the transplacental transfer of ZIKV to the fetus, indicating a unique pathway for intrauterine transmission. Hofbauer placental macrophages release type I IFN and increase interferon-stimulated genes (ISGs) in response to ZIKV infection, but the cells still allow ZIKV replication. Figure 7C shows how the placental syncytiotrophoblasts’ production of IFN-λ1 and ISGs during the later stages of pregnancy may have protective effects that prevent ZIKV infection. Figure 7D shows how ZIKV specifically targets neural progenitor cells during the embryonic brain’s development in first trimester. The entry of ZIKV into brain cells may be significantly influenced by the TAM receptor AXL. Deregulation of genes involved in neuronal development and apoptosis brought on by ZIKV-dependent activation of TLR3-mediated immune responses leads to significant damage to the embryonic brain, including microcephaly (33).
Cellular mechanism of ZIKV
ZIKV presumably enters the cell by receptor-mediated endocytosis (28). The endocytosis is either clathrin or receptor mediated. A fusion between the virus and the host cell occurs because of the acidic environment and genomic RNA released inside the host cell. After its release, viral RNA is translated to the polyprotein in the vicinity of the endoplasmic reticulum (ER) with the help of viral-encoded proteins and the host. Later, viral replication and packaging occur on the surface of ER of the host cell. Furin-mediated cleavage occurs at the Golgi complex, resulting in the formation of a mature virus. Virus particles are released with the help of exocytosis, and ZIKV activates a TLR3-mediated immune response and autophagy pathway (34, 35). This may mediate viral survival and replication inside the cell, and then exosomes containing the ZIKV proteins are released by the infected cells (36). ZIKV may activate the unfolded protein response pathway, which may lead to cell death, DNA repair, or homeostasis (37, 38). The cellular mechanism of ZIKV is shown in Figure 8.
Figure 8
Diagnosis of ZIKV
It is difficult to diagnose ZIKV infections because in more than 80% of cases ZIKV is asymptomatic. The symptoms of ZIKV infection overlap with those of infection with other flaviviruses. To date, five serological assays and 14 molecular diagnostics tests (Table 1), based on serum, saliva, and urine samples collected from patients, have been approved by the United States Food and Drug Administration (FDA) (39). In the case of individuals whose symptoms started within the previous 7 days, ZIKV infection can be diagnosed by subjecting whole blood or serum to an RT-PCR (reverse transcription-polymerase chain reaction) test known as nucleic acid testing (NAT). Enzyme immunoassays (EIAs), immunofluorescence assays (IFAs), and neutralization assays, such as plaque-reduction neutralization tests (PRNTs), are crucial serological diagnostic tools, nonetheless, and should be used in individuals with symptoms that have persisted for more than 7 days (40). Serological assays should be interpreted carefully, as cross-reactivity between dengue and ZIKV antibodies may lead to misidentification of the causative agent, and prior exposure may also give false-positive results. Thus, serological assays alone cannot confirm ZIKV infection (41). Quantitative reverse transcription is used in in vitro diagnostics (IVDs). The most accurate molecular diagnostic method for ZIKV is PCR (i.e., qRT-PCR); however, due to its high cost and mobility issues, its use as a point-of-care (POC) test during monitoring programs is constrained (42). Instead, because of their low cost and simple logistical handling, reverse transcription loop-mediated amplification (RT-LAMP) and microfluidic cassettes are more popular (40, 43). Pregnant women with ZIKV infection living in endemic areas and with a history of clinical illness should undergo routine ultrasound scans in early pregnancy to check for abnormalities or fetal malformation (44). In pregnant women, ZIKV infection should be diagnosed based on laboratory evidence. Detection of RNA in blood and urine confirms ZIKV infection, whereas detection by IgM testing may give a false-positive result because of prior infection (41).
Table 1
| Method for detection | ZIKV antigen | Sample type | Method | Name |
|---|---|---|---|---|
| Serological assays | Complete virus | Serum | MAC-ELISA | ZIKV MAC-ELISA |
| Envelope | Serum | MAC-ELISA | ZIKV Detect IgM capture ELISA | |
| NS1 | Serum | Microparticle IgM capture immunoassay | Liaison XL Zika capture IgM assay | |
| Serum, plasma | Microparticle IgM capture immunoassay | ADVIA Centaur Zika test | ||
| Fingerstick or venous whole blood, serum, plasma | Immunochromatographic | DPP Zika IgM system | ||
| Molecular diagnostic test | Envelope | Whole blood, serum, cerebrospinal fluid, urine, amniotic fluid | RT-PCR (TaqMan) | Trioplex Real-time RT-PCR Assay |
| Serum, urine | RT-PCR (TaqMan) | Zika virus RNA qualitative real-time RT PCR | ||
| NS1 | Serum, urine | RT-PCR (TaqMan) | RealStar Zika virus RT-PCR kit | |
| Serum, plasma, urine | Transcription-mediated amplification | Aptima Zika virus assay | ||
| NS4/NS5 | Serum, plasma, urine | Transcription-mediated amplification | Aptima Zika virus assay | |
| Serum, plasma, urine | RT-PCR | Sentosa SA ZIKV RT-PCR test | ||
| 3′ untranslated region | Serum, urine | RT-PCR | CII-ArboViroPlexrRT-PCR | |
| NS3 and Premembrane | Whole blood, serum, plasma, urine | RT-PCR | RealTime Zika, Zika ELITe MGB kit U.S. | |
| Not specified | Serum, plasma, urine | RT-PCR (TaqMan) | Zika virus real-time RT-PCR test, Versant Zika RNA 1.0 assay, xMAPMultiFLEX Zika RNA assay, Zika virus detection by RT-PCR, Gene-RADAR Zika virus test, TaqPath Zika virus kit |
Treatment of ZIKV
As yet, no specific vaccine against ZIKV infection is available, and treatment includes symptomatic care, for example, plenty of water intake, rest, antipyretics, and analgesics (45). ZIKV vaccine development is the subject of extensive study and includes several vaccine types, e.g., DNA-based vaccines, subunit vaccines, inactivated vaccines, and live-attenuated vaccines (46). Some antiviral drugs are also prescribed against ZIKV. GBS can be treated by intravenous injection of immunoglobins (0.4 g/kg body weight daily for 5 days) and by plasma exchange (200–250 ml plasma/kg body weight in five sessions) (47).
Antiviral drugs
A variety of methods have been used to find medications that can fight ZIKV infection. Despite the serious consequences for public health, there is presently no cure or medicine to prevent ZIKV infections. On the basis of mode of action, ZIKV antivirals can be classified into host-directing antivirals and direct-acting antivirals. Efforts to develop effective antiviral drugs have focused on drug repositioning, as this minimizes the number of clinical trial steps. The search for drugs suitable for repositioning has helped pregnant women and newborns to withstand the outbreaks of ZIKV (48, 49). Of the repositioning drugs listed in Table 2, only temoporfin can be given to pregnant women (49). The anti-ZIKV medications sofosbuvir, chloroquine, and suramin produced better outcomes because more experimental data were available for evaluation (48). To facilitate the search for and increase the chances of finding a suitable anti-ZIKV medicine, other medications’ effectiveness against ZIKV should also be assessed.
Table 2
| Sr. No. | Drug | Mechanism | Primary specification | Reference |
|---|---|---|---|---|
| 1. | Sofosbuvir | Inhibit ZIKV RNA polymerase | Hepatitis C infection | 50 |
| 2. | Chloroquine and its derivatives | Inhibit ZIKV replication by inhibiting RNA polymerase and protein synthesis | Antimalarial compound | 51 |
| 3. | Suramin | Blocking viral adsorption | Anthelmintic drug | 52 |
| 4. | Niclosamide | Inhibit interaction between NS3 and NS2B, protease inactivation | Anthelmintic drug | 53 |
| 5. | Mefloquine | Prevent ZIKV replication and autophagy | Antimalaria drug | 54 |
| 6. | Non-steroidal anti-inflammatory drugs (NSAIDs) | Reduced expression of AXL receptors | Against fever and analgesia | 55 |
| 7. | Statins | Inhibit ZIKV replication | Cancer and neurological disorders | 56 |
| 8. | Ribavirin | NS5 polymerase inhibitor | Hepatitis C infection | 57 |
| 9. | Emetine | NS5 polymerase inhibitor Disruption of lysosomal function | Dengue virus infection | 58 |
| 10. | Temoporfin | Inhibit interaction between NS3 and NS2B | Adenocarcinoma and other cancers | 53 |
| 11. | Artemisinin | Prevent ZIKV replication | Malaria treatment | 59 |
| 12. | Berberine | Inhibit ZIKV replication by binding with NS3 protease | Anti-diabetic and anti-cancer | 60 |
| 13. | Cephalotaxine | Blocks RNA translation, interferes with cell cycle progression | Anti-cancer | 61 |
| 14. | Quercetin | Inhibits viral protease and ZIKV replication | Anti-carcinogenic and anti-histamine | 62 |
| 15. | Nanchangmycin | Envelope glycoprotein inhibitor | Insecticidal and anti-bacterial | 63 |
| 16. | MYD1 | Binds to Gas6, blocks ZIKV binding to the AXL receptor | Antagonist of the AXL/Gas6 pathway | 31 |
| 17. | R428 | Inhibits phosphorylation of AXL | Antagonist of the AXL/Gas6 pathway | 31 |
| 18. | Emricasan | Proliferation decreases, and ZIKV replication should be somewhat protected for hNPC | Pan-caspase inhibitor | 64 |
| 19. | Seliciclib | Caspase inhibitor, inhibits ZIKV replication | Anti-cancer | 64 |
| 20. | Bithionol | Blocks ZIKV-induced caspases | Anti-helminthic | 65 |
| 21. | NGI-1 | Inhibits viral RNA production and replication | Oligosaccharyltransferase inhibitor | 66 |
| 22. | 6-Methylmercaptopurine riboside/6MMPr | Blocks de novo production of purines | Antiviral against hepatitis C virus, dengue virus, and yellow fever virus | 67 |
| 23. | Heparin | Exhibits anti-apoptotic activity in hNPCs | Anti-coagulant | 68 |
| 24. | Memantine | Inhibits glutamate receptors and reduces neurodegeneration | Alzheimer’s disease treatment | 69 |
| 25. | Azithromycin | Lowers the rate of cellular apoptosis in cellular glial cells | Antibiotic | 70 |
| 26. | IL-1 receptor antagonist/anakinra (Kineret) | Prenatal microglial activity is inhibited to reduce fetal neuroinflammation. | Rheumatoid arthritis treatment | 71 |
| 27. | Favipiravir (6-fluoro-3- hydroxy-2-pyrazinecarboxamide or T-705) | Up-regulates AKT phosphorylation, promotes neuronal cell growth | RdRp inhibitor and antiviral | 57 |
Repositioned anti-ZIKV drugs.
ZIKV vaccines
ZIKV infection induces both innate and adaptive immune responses. The innate immune response is the first line of defense against ZIKV. ZIKV infection triggers type I interferons and signaling, which may inhibit ZIKV, but ZIKV exhibits different mechanisms to interfere with IFN induction. Non-structural proteins play an important role in IFN inhibition. The humoral immune response is protective against ZIKV, and specific neutralizing antibodies are produced against the E protein. Vertical transmission is inhibited by recognizing a quaternary epitope on the E protein dimer–dimer, by recognizing the lateral ridge epitope of domain III of the E protein, and by recognizing a quaternary epitope spanning all three domains of the E protein. However, this may lead to the enhancement of dengue virus replication and a phenomenon known as ADE (i.e., antibody-dependent enhancement) (72). Therefore, the vaccine must be designed by taking into consideration the phenomenon of ADE. In addition, understanding the correlation between immunity and infection is difficult, as different levels of adaptive immune response also differ from individual to individual, depending on age, sex, and health conditions, and correlation also differs in animal models, making it difficult to understand the effect on human beings, especially neonates, as ethical issues will be faced. Despite these shortcomings and limitations, many vaccine candidates have been developed to fight against ZIKV. Developing a safe and effective vaccine against ZIKV will help in preventing the spread of ZIKV, and save people from its adverse effects. Various kinds of vaccines against ZIKV infection, for example, DNA vaccines, mRNA vaccines, live-attenuated vaccines, virus-like protein vaccines, subunit vaccines, virus-vectored vaccines, and purified inactivated vaccines, have been tested in preclinical studies in non-human primates and in clinical trials in humans (Tables 3, 4).
Table 3
| Sr. No. | Vaccine type | Component of vaccine | Name of vaccine | Animal model | Vaccine dose | Administration mode | Virus challenged | Results | Reference |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNA vaccine | prM and E | ZIKV-prME | Type I interferon knockout mice | Two doses are given 2 weeks apart | Intramuscular injection | Puerto Rico Strain PRVABC59 | Completely protected mice against sperm and testes damage brought on by ZIKV and stopped the virus’ persistence in the testes | 73 |
| pVAX1-ZME | BALB/c mice | Three doses of vaccine given in 3 weeks | Intramuscular injection | (SMGC-1 strain, GenBank accession number KX266255 | Passive defense against ZIKV infection in newborn mice by eliciting potent, long-lasting adaptive immune responses with high and sustained ZIKV-specific neutralizing activity | 74 | |||
| GLS-5700 | C57BL/6J mice and IFNAR−/− mice | Two doses were given, 2 weeks apart | Intramuscular injection | Puerto Rico Strain PRVABC59 | Prevented male IFNAR/mice from losing their fertility | 75 | |||
| ABC/prM-E | C57BL/6c mice | Days 0, 24, 42, and 199: four doses | Intramuscular injection | Puerto Rico Strain PRVABC59 | Elicited defenses against many different ZIKV isolates | 76 | |||
| NS1 | pVAX-NS1, pVAX-tpaNS1, pVAX-tpaNS1- IMX313P (NS1) | BALB/c and, type I IFN receptor–deficient−/− mice | Three doses were given, one every 2 weeks | Intradermal injection | ZIKVzkv2015 | When compared to pVAX-NS1 and pVAX-tpaNS1- IMX313P, pVAX-tpaNS1 immunization dramatically increased NS1-specific antibody titers and CD4+ and CD8+ T-cell responses | 77 | ||
| 2 | Subunit vaccine | E | Recombinant ZIKV E | Swiss Webster, BALB/c, and C57BL/6 mice | In 3 weeks, three doses of vaccine were given | Intramuscular injection | Puerto Rico Strain PRVABC59 | The animals produced significant amounts of neutralizing antibodies and antigen-binding IgG titers, which offered protection from viremia after ZIKV infection | 78 |
| Recombinant ZIKV E | Cynomolgus macaques and BALB/c mice | Three doses of vaccine spaced 3 weeks apart | Intramuscular injection | Puerto Rico Strain PRVABC59 | High neutralizing antibody titers were induced | 79 | |||
| E-Domain III | EDIII | C57BL/6 mice | Four doses were given at intervals of 3 weeks | Subcutaneous injection | Puerto Rico Strain PRVABC59 | No signs of ADE development were exhibited in mouse serum and produced strong titers of IgG and ZIKV-neutralizing antibodies | 80 | ||
| EDIII (having fragments 296 to 406; 298 to 409; 301 to 404) | BALB/c mice and A129 mice | Five doses of vaccine were given at time intervals of 0, 21, 42, 210, and 300 | Intramuscular injection | R103451 and FLR strains | ZIKV infection was prevented in infants and immunocompromised adults by passive transfer of the vaccine-specific antibodies and induced persistent broad-spectrum neutralizing antibodies | 81 | |||
| 450 amino acids of E-protein | E90 | CR (CD-1 immunocompetent) mice; BALB/c mice | In 2 weeks, two dosages of vaccine were given | Intraperitoneal injection | GZ01 and FSS13025 strains | E90 immunization of pregnant mice protected against ZIKV infection and microcephaly by protecting brain development in offspring both during gestation and in the neonatal period. E90 induced strong humoral responses that were unique to the ZIKV in adult BALB/c mice | 82 | ||
| 3 | Live attenuated vaccine | ZIKV RNA genome | ZIKV-30 UTR-10-LAV | A129 mice | One dosage | Subcutaneous injection | Cambodian strain FSS13025 and Puerto Rico strain PRVABC59 | Demonstrated total protection against viremia and elicited a saturation neutralizing antibody response | 83 |
| ZIKV-30 UTR-20-LAV | A129 mice and rhesus macaques | One dosage | Subcutaneous injection | Cambodian strain FSS13025 and Puerto Rico strain PRVABC59 | Generated potent immune responses and protected mice against ZIKV-induced testicular injury; promoted sterilizing immunity in non-human primates | 83 | |||
| NS1 | ZIKV-NS1-LAV (NS1) | A129 mice and rhesus macaques | One dosage | Subcutaneous injection | Puerto Rico strain PRVABC59 | Significantly reduced viral RNA levels were found in the tissues of the mother, the placenta, and the fetus, and this provided protection against placental injury and fetal mortality | 84 | ||
| 9 amino-acids deleted region of C-protein | LAV | A129 mice | One dosage | Subcutaneous injection | Puerto Rico strain PRVABC59 | In addition to inducing protective immunity that entirely shielded against viremia, morbidity, and death, it also entirely protected against infection in pregnant mice and transfer from mother to fetus | 85 | ||
| 4 | Virus vector-based vaccine | prM and E gene, E1 region of Adenovirus 4 & 5 | Ad4-prM-E and Ad5-prM-E | C57BL/6 mice | In 3 weeks, two doses of vaccine were given | Intramuscular injection | Puerto Rico strain PRVABC59 | Vaccination with Ad5-prM-E elicited both humoral and cellular responses, whereas Ad4-prM-E elicited cellular response | 86 |
| prM and E gene, replication deficient human Ad5 | hAd5-prM-E | C57BL/6 mice and Ifnar1−/− mice | One dosage | Intranasal injection | Puerto Rico strain PRVABC59 | Immunological responses were triggered on the humoral and cell-mediated levels, providing defense against ZIKV infection | 87 | ||
| Ad5, prM, E, signal peptide and Ad5, E | Ad5-Sig-prM-Env (prM-E) and Ad5-Env (E) | BALB/c mice and A129 mice | One dosage | Intramuscular injection | Puerto Rico strain PRVABC59 | Both vaccines produced strong adaptive immunity in immunodeficient BALB/c mice and A129 mice, although Ad5-Sig-prM-Env-vaccinated animals exhibited significantly higher ZIKV-specific neutralizing antibody titers and lower viral loads than Ad5-Env-vaccinated mice | 88 | ||
| Chimpanze Ad, prM, E | ChAdOx1 | BALB/c mice | One dose | Intramuscular injection | Brazilian ZIKV | A strong immune response generated against ZIKV in challenged mice | 89 | ||
| prM, E, Rhesus Ad52 | RhAd52-prMEnv | Rhesus monkeys and BALB/c mice | One dose | Intramuscular injection | Brazilian ZIKV and Puerto Rico strain PRVABC59 | Rhesus monkeys were induced to produce ZIKV-specific neutralizing antibodies; mice developed antibodies protective enough against ZIKV challenge | 90 | ||
| prM, E, NS1 | rVSV-prM-E-NS1 | A129 mice and BALB/c mice | One dose | Intranasal injection | Cambodian strain FSS13025 | T-cell immune responses and ZIKV-specific antibodies were induced, providing significant protection against infection | 91 | ||
| Vesicular stomatitis virus (VSV)- capsid and VSV, E (260–425) | VSV-Capsid and VSV-ZikaE | BALB/c mice | One dose | Intranasal injection | Puerto Rico strain PRVABC59 | In inoculated BALB/c mice, both vaccines produced potent ZIKV-specific humoral responses; however, the VSV-capsid vaccine elicited noticeably larger numbers of IFN+ CD8+ and CD4+ T-cells than the VSV-ZikaE260–425 vaccine | 92 | ||
| 5 | Purified in activated vaccine | Purified inactivated ZIKV vaccine with alum-adjuvant | PIZV | CD-1 and AG129 mice | In 4 weeks, three doses of the vaccine were given | Intramuscular injection | Puerto Rico strain PRVABC59 | A fatal ZIKV challenge could not kill AG129 mice after and was found to be immunogenic in a model animal. Complete protection against a deadly ZIKV challenge was also demonstrated by the passive transfer of ZIKV-immune serum to naive mice | 93 |
| BALB/c mice and cynomolgus macaques | Two doses at 3/4-week intervals | Intramuscular injection | Puerto Rico strain PRVABC59 | Provided full protection against ZIKV similar strain and produced strong neutralizing antibody responses | 94 | ||||
| Purified inactivated ZIKV vaccine | PIZV | Indian rhesus macaques | Two doses of vaccine at a 4 weeks spaced | Intramuscular injection | Puerto Rico strain PRVABC59 | Induced long-lasting, dose-dependent neutralizing antibody reactions | 95 | ||
| Rhesus macaques | In 4 weeks, two doses of the vaccine were given | Subcutaneous injection, Intramuscular injection | Brazil ZKV2015 | A strong defense against the ZIKV challenge was provided by the two doses of vaccine | 96 | ||||
| 6 | Virus-like particle-based vaccine | prM and E with HEK293 vector | ZIKV VPLs | AG129 mice | Two doses were given on days 0 and 32 | Intramuscular injection | Prototype Zika Nica 2–16 strain | Induced a protective antibody response | 97 |
| prM and E with baculovirus vector | BALB/c mice | Three dosages of vaccine in 2 weeks | Intramuscular injection | ZIKV strain SZ-WIV01 | T-cell responses, ZIKV-specific IgG, and neutralizing antibodies were stimulated | 98 | |||
| EDIII with Nicotiana benthamiana | C57BL/6 mice | Three dosages were given in 3 weeks | Subcutaneous injection | Puerto Rico strain PRVABC59 | Immune responses that were elicited were strong on the humoral and cellular levels, and they were protective against various strains | 99 | |||
| 7 | mRNA-based vaccine | prM and E | sr-prM-E-mRNA ZIKV vaccine | BALB/c and IFNAR−/− C57BL/6 mice | In 4 weeks, two doses of the vaccine were given | Intradermal injection | ZIKV strain MR-766 | As little as 1 µg of this vaccine electroporated into the skin of BALB/c and IFNAR/C57BL/6 mice evoked powerful humoral and cellular immunological responses, completely protecting the mice from ZIKV infection | 100 |
| IgE-prM-E LNP vaccine | AG129, BALB/c and C57BL/6 mice | A single dose and two doses were given in 3 weeks | Intramuscular injection | African ZIKV strain (Dakar 41519) | When immune-competent mice were protected from ZIKV infection and provided sterilizing immunity, ADE was reduced both in vitro and in vivo | 101 | |||
| Nucleoside-modified ZIKV prM-E mRNA-LNP vaccine | BALB/c and C57BL/6 mice; rhesus macaques (Macaca mulatta) | One dosage | Intradermal injection | Puerto Rico strain PRVABC59 | Robust and long-lasting protective responses in mice and non-human primates | 102 |
Different pre-clinical studies of ZIKV vaccine.
•This table has been adopted from (104) with some modifications.
Table 4
| Type of vaccine | Vaccine name | Immunogen | Vaccine trials accession no. | Phase |
|---|---|---|---|---|
| DNA vaccine | GLS-5700 | prM and E | NCT02809443 | 1 |
| GLS-5700 | prM and E | NCT02887482 | 1 | |
| VRC-ZKADNA085-00-VP | prM and E | NCT02840487 | 1 | |
| VRC-ZKADNA090-00-VP | prM and E | NCT02996461 | 1 | |
| VRC-ZKADNA090-00-VP | prM and E | NCT03110770 | 2 | |
| Inactivated complete ZIKV | Zika virus, purified inactivated VACCINE (ZIKV PIV) | Inactivated virus and aluminum salts | NCT02963909 | 1 |
| ZIKV PIV | Inactivated virus and aluminum salts | NCT02952833 | 1 | |
| ZIKV PIV | Inactivated virus and aluminum salts | NCT02937233 | 1 | |
| ZIKV PIV | Inactivated virus and aluminum salts | NCT03008122 | 1 | |
| PIZV or TAK-426 | Inactivated virus and aluminum salts | NCT03343626 | 1 | |
| VLA1601 | Inactivated virus and aluminum salts | NCT03425149 | 1 | |
| BBV121 | Inactivated virus and aluminum salts | CTRI/2017/05/008539 | 1 | |
| Virus-vectored vaccine | ZIKV/D4Δ30-713 | Backbone of DENV, prM, and E | NCT03611946 | 1 |
| MV-Zika | prM and E | NCT02996890 | 1 | |
| Peptide | AGS-v | Mosquito salivary proteins | NCT03055000 | 1 |
| mRNA vaccine | mRNA-1325 | prM and E | NCT03014089 | 2 |
ZIKV vaccines that are currently undergoing clinical trials (103).
Preventive measures for ZIKV
As there is no treatment, prevention is the best method of protecting against ZIKV, either by protection from mosquito bites or by controlling the vector population (105). In ZIKV-prone areas, populations should be controlled by using mosquito repellents, such as DEET (N,N-diethyl-m-toluamide), bed nets, window screens, and applying permethrin cream on skin and clothes (106). At the moment, the best method for preventing and controlling arboviral infections such as Zika is comprehensive vector management. Vector management includes environment management practices such as destroying breeding sites (e.g., stagnant water, dumping grounds, landfill sites) by spraying larvicides and insecticides (105). Prevention of the sexual transmission of ZIKV requires the use of reliable contraceptives or abstinence at the time of ZIKV infection (107). All of these are temporary methods, as mosquitoes are becoming insecticide resistant. A safe and effective vaccination or antiviral medication is, thus, required to treat ZIKV infection permanently.
Conclusion
The re-emergence of ZIKV has frightened the world. Although there are now fewer cases, there remains the risk of outbreaks in the future. There is uncertainty about the occurrence of ZIKV. Scientists, governments, public health officials, and pharmaceutical companies should come together and prepare to fight strongly the next ZIKV outbreak. There is a need for a safe and effective vaccine to fight against ZIKV, as there are some unknown mechanisms that help the virus to escape. It is possible that the ability of the virus to vertically transmit in mosquitoes, and its increasing vector competency, helps it to cope with harsh conditions and re-emerge as an outbreak. More studies should be carried out in this context. Understanding the interaction between the host and ZIKV will also help in developing different therapeutics against ZIKV infection. There is a need for more effort to prevent and treat ZIKV. Vaccine development and the use of vaccines against any pandemic depends on factors such as animal models for preclinical studies, validation of vaccines by assuring their safety (including safety for pregnant women and neonates), production at massive levels, and clinical trials. More studies should be conducted to determine the effects of vaccines on pregnant women, fetal development, infants, and elderly individuals. As some vaccines are under clinical trial, they should be tested further for any side effects. Work/tests must also be carried out to bring a ZIKV vaccine to licensure and public use. As cases of ZIKV have significantly reduced, a controlled human infection model should be developed to test the efficacy and correlation in humans; however, due to a lack of support, it has become difficult to develop such models. This will adversely affect ZIKV vaccine development projects and can threaten the public in the event of a sudden outbreak, as was seen in the case of COVID-19. Therefore, there is a need for a scientific society that can predict outbreaks and prepare to fight against such outbreaks.
Statements
Author contributions
ND: manuscript drafting, writing, and reviewing. MY: information collection, reviewing the manuscript, and editing. HS and RJ helped in reviewing and editing. NS: manuscript conceptualization, reviewing, and editing. All authors contributed to the article and approved the submitted version.
Acknowledgments
The authors are grateful to Maharshi Dayanand University for providing University Research Scholarship to ND and MY.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
World Health Organization. “Zika epidemiology update.” World health organization. (2019) https://www.who.int/publications/m/item/zika-epidemiology-update.
2
GrantAPoniaSSTripathiSBalasubramaniamVMiorinLSourisseauMet al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe (2016) 19:882–90. doi: 10.1016/j.chom.2016.05.009
3
World Health Organization. Zika situation report: Zika virus, microcephaly and Guillain-Barré syndrome.”(2016). Available at: https://apps.who.int/iris/handle/10665/250633.
4
PergolizziJLeQuangJAUmeda-RaffaSFleischerCPergolizziIIIJPergolizziCet al. The zika virus: Lurking behind the COVID-19 pandemic? J Clin Pharm Ther (2021) 46:267–76. doi: 10.1111/jcpt.13310
5
KhanEJindalHMishraPSuvvariTKJonnaS. The 2021 zika outbreak in uttar pradesh state of India: Tackling the emerging public health threat. Trop Doctor. (2022) 52:474–8. doi: 10.1177/00494755221113285
6
SáfadiMAAlmeidaFJde Ávila KfouriR. Zika virus outbreak in Brazil–lessons learned and perspectives for a safe and effective vaccine. Anatomical Rec (2021) 304:1194–201. doi: 10.1002/ar.24622
7
DahiyaNYadavMYadavASehrawatN. Zika virus vertical transmission in mosquitoes: A less understood mechanism. J Vector Borne Diseases. (2022) 59:37–44. doi: 10.4103/0972-9062.331411
8
RatherIALoneJBBajpaiVKPaekWKLimJ. Zika virus: An emerging worldwide threat. Front Microbiol (2017) 8:1417. doi: 10.3389/fmicb.2017.01417
9
SongBHYunSIWoolleyMLeeYM. Zika virus: History, epidemiology, transmission, and clinical presentation. J neuroimmunology. (2017) 308:50–64. doi: 10.1016/j.jneuroim.2017.03.001
10
Gutiérrez-BugalloGPiedraLARodriguezMBissetJALourenço-de-OliveiraRWeaverSCet al. Vector-borne transmission and evolution of zika virus. Nat Ecol evolution. (2019) 3:561–9. doi: 10.1038/s41559-019-0836-z
11
ThamHWBalasubramaniamVOoiMKChewMF. Viral determinants and vector competence of zika virus transmission. Front Microbiol (2018) 9:1040. doi: 10.3389/fmicb.2018.01040
12
MussoDNillesEJCao-LormeauVM. Rapid spread of emerging zika virus in the pacific area. Clin Microbiol Infection. (2014) 20(10):O595–6. doi: 10.1111/1469-0691.12707
13
MillerBRMonathTPTabachnickWJEzikeVI. Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol (1989) 40(4):396–9.
14
Del Carpio-OrantesLdel Carmen González-ClementeMLamothe-AguilarT. Zika and its vector mosquitoes in Mexico. J Asia-Pacific Biodiversity. (2018) 11(2):317–9. doi: 10.1016/j.japb.2018.01.002
15
ObadiaTGutierrez-BugalloGDuongVNunezAFernandesRKamgangBet al. Zika vector competence data reveals risks of outbreaks: the contribution of the European ZIKAlliance project. Nat Commun (2022) 13(1):1–8. doi: 10.1038/s41467-022-32234-y
16
MussoDKoAIBaudD. Zika virus infection–after the pandemic. New Engl J Med (2019) 381(15):1444–57. doi: 10.1056/NEJMra1808246
17
de OliveiraWKCortez-EscalanteJDe OliveiraWTCarmoGMHenriquesCMCoelhoGEet al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed zika virus transmission during the first trimester of pregnancy–Brazil, 2015. Morbidity Mortality Weekly Rep (2016) 65(9):242–7. doi: 10.15585/mmwr.mm6509e2
18
BaudDGublerDJSchaubBLanteriMCMussoD. An update on zika virus infection. Lancet (2017) 390(10107):2099–109. doi: 10.1016/S0140-6736(17)31450-2
19
FreitasDASouza-SantosRCarvalhoLMBarrosWBNevesLMBrasilPet al. Congenital zika syndrome: A systematic review. PloS One (2020) 15(12):e0242367. doi: 10.1371/journal.pone.0242367
20
Cao-LormeauVMBlakeAMonsSLastèreSRocheCVanhomwegenJet al. Guillain-Barré Syndrome outbreak associated with zika virus infection in French Polynesia: a case-control study. Lancet (2016) 387(10027):1531–9. doi: 10.1016/S0140-6736(16)00562-6
21
ShahrizailaNLehmannHCKuwabaraS. Guillain-Barré Syndrome. Lancet (2021) 397(10280):1214–28. doi: 10.1016/S0140-6736(21)00517-1
22
Del Carpio OrantesL. Guillain-Barré Syndrome associated with zika virus infection in the americas: A bibliometric study. Neurologia (Barcelona Spain). (2018) 35(6):426–9.
23
Del Carpio OrantesLMéndezCIGarcíaRJGarcíaANCabreraYLSalgueroLSet al. Síndrome de Guillain Barré asociado a los brotes de zika, de brasil a méxico. Neurología Argentina. (2020) 12(3):147–52. doi: 10.1016/j.neuarg.2020.06.002
24
TangHHammackCOgdenSCWenZQianXLiYet al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell (2016) 18(5):587–90. doi: 10.1016/j.stem.2016.02.016
25
BhagatRPrajapatiBNarwalSAgnihotriNAdlakhaYKSenJet al. Zika virus e protein alters the properties of human fetal neural stem cells by modulating microRNA circuitry. Cell Death Differentiation. (2018) 25(10):1837–54. doi: 10.1038/s41418-018-0163-y
26
GarcezPPLoiolaECMadeiro da CostaRHigaLMTrindadePDelvecchioRet al. Zika virus impairs growth in human neurospheres and brain organoids. Science (2016) 352(6287):816–8. doi: 10.1126/science.aaf6116
27
NowakowskiTJPollenAADi LulloESandoval-EspinosaCBershteynMKriegsteinAR. Expression analysis highlights AXL as a candidate zika virus entry receptor in neural stem cells. Cell Stem Cell (2016) 18(5):591–6. doi: 10.1016/j.stem.2016.03.012
28
SmitJMMoeskerBRodenhuis-ZybertIWilschutJ. Flavivirus cell entry and membrane fusion. Viruses (2011) 3(2):160–71. doi: 10.3390/v3020160
29
HamelRDejarnacOWichitSEkchariyawatPNeyretALuplertlopNet al. Biology of zika virus infection in human skin cells. J virology. (2015) 89(17):8880–96. doi: 10.1128/JVI.00354-15
30
KomarasamyTVAdnanNAJamesWBalasubramaniamVR. Zika virus neuropathogenesis: The different brain cells, host factors and mechanisms involved. Front Immunol (2022) 13:773191–. doi: 10.3389/fimmu.2022.773191
31
MeertensLLabeauADejarnacOCiprianiSSinigagliaLBonnet-MadinLet al. Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses. Cell Rep (2017) 18(2):324–33. doi: 10.1016/j.celrep.2016.12.045
32
WangZYWangZZhenZDFengKHGuoJGaoNet al. Axl is not an indispensable factor for zika virus infection in mice. J Gen virology. (2017) 98(8):2061. doi: 10.1099/jgv.0.000886
33
OlagnierDMuscoliniMCoyneCBDiamondMSHiscottJ. Mechanisms of zika virus infection and neuropathogenesis. DNA Cell Biol (2016) 35(8):367–72. doi: 10.1089/dna.2016.3404
34
DangJTiwariSKLichinchiGQinYPatilVSEroshkinAMet al. Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell (2016) 19(2):258–65. doi: 10.1016/j.stem.2016.04.014
35
LiangQLuoZZengJChenWFooSSLeeSAet al. Zika virus NS4A and NS4B proteins deregulate akt-mTOR signaling in human fetal neural stem cells to inhibit neurogenesis and induce autophagy. Cell Stem Cell (2016) 19(5):663–71. doi: 10.1016/j.stem.2016.07.019
36
ZhangZWLiZLYuanS. The role of secretory autophagy in zika virus transfer through the placental barrier. Front Cell infection Microbiol (2017) 6:206. doi: 10.3389/fcimb.2016.00206
37
BlázquezABEscribano-RomeroEMerino-RamosTSaizJCMartín-AcebesMA. Stress responses in flavivirus-infected cells: activation of unfolded protein response and autophagy. Front Microbiol (2014) 5:266. doi: 10.3389/fmicb.2014.00266
38
OjhaCRRodriguezMLapierreJMuthu KaruppanMKBranscomeHKashanchiFet al. Complementary mechanisms potentially involved in the pathology of zika virus. Front Immunol (2018) 9:2340. doi: 10.3389/fimmu.2018.02340
39
TheelESHataDJ. Diagnostic testing for zika virus: a postoutbreak update. J Clin Microbiol (2018) 56(4):e01972-17. doi: 10.1128/JCM.01972-17
40
BhardwajUPandeyNRastogiMSinghSK. Gist of zika virus pathogenesis. Virology (2021) 560:86–95. doi: 10.1016/j.virol.2021.04.008
41
World Health Organization. Laboratory testing for zika virus and dengue virus infections: interim guidance(2022). Available at: https://www.who.int/publications/i/item/WHO-ZIKV_DENV-LAB-2022.1.
42
SilvaSJMHPDRGKrokovskyLFLMMASet al. Development and validation of reverse transcription loop-mediated isothermal amplification (RT-LAMP) for rapid detection of ZIKV in mosquito samples from Brazil. Sci Rep (2019) 9(1):1–2. doi: 10.1038/s41598-019-40960-5
43
MaukMGSongJBauHHLiuC. Point-of-care molecular test for zika infection. Clin Lab Int (2017) 41:25.
44
World Health Organization. Pregnancy management in the context of zika virus: interim guidance (No. WHO/ZIKV/MOC/16.2 rev. 1). World Health Organization (2016). Available at: https://www.who.int/publications/i/item/WHO-ZIKV-MOC-16.2-Rev.1.
45
ChanJFChoiGKYipCCChengVCYuenKY. Zika fever and congenital zika syndrome: an unexpected emerging arboviral disease. J Infection. (2016) 72(5):507–24. doi: 10.1016/j.jinf.2016.02.011
46
PolandGAKennedyRBOvsyannikovaIGPalaciosRHoPLKalilJ. Development of vaccines against zika virus. Lancet Infect diseases. (2018) 18(7):e211–9. doi: 10.1016/S1473-3099(18)30063-X
47
LeonhardSEMandarakasMRGondimFABatemanKFerreiraMLCornblathDRet al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurology. (2019) 15(11):671–83. doi: 10.1038/s41582-019-0250-9
48
RampiniDPrietoDCColziALde AraújoRVGiarollaJ. Future and perspectives of the zika virus: Drug repurposing as a powerful tool for treatment insights. Mini Rev Medicinal Chem (2020) 20(18):1917–28. doi: 10.2174/1389557520666200711174007
49
TanLYKomarasamyTVJamesWBalasubramaniamVR. Host molecules regulating neural invasion of zika virus and drug repurposing strategy. Front Microbiol (2022) 13. doi: 10.3389/fmicb.2022.743147
50
SacramentoCQde MeloGRde FreitasCSRochaNHoelzLVMirandaMet al. The clinically approved antiviral drug sofosbuvir inhibits zika virus replication. Sci Rep (2017) 7(1):1–2. doi: 10.1038/srep40920
51
ShiryaevSAMesciPPintoAFernandesISheetsNShrestaSet al. Repurposing of the anti-malaria drug chloroquine for zika virus treatment and prophylaxis. Sci Rep (2017) 7(1):1–9. doi: 10.1038/s41598-017-15467-6
52
AlbulescuICKovacikovaKTasASnijderEJvan HemertMJ. Suramin inhibits zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res (2017) 143:230–6. doi: 10.1016/j.antiviral.2017.04.016
53
LiZBrecherMDengYQZhangJSakamuruSLiuBet al. Existing drugs as broad-spectrum and potent inhibitors for zika virus by targeting NS2B-NS3 interaction. Cell Res (2017) 27(8):1046–64. doi: 10.1038/cr.2017.88
54
Barbosa-LimaGMoraesAMAraújoADda SilvaETde FreitasCSVieiraYRet al. 2, 8-bis (trifluoromethyl) quinoline analogs show improved anti-zika virus activity, compared to mefloquine. Eur J medicinal Chem (2017) 127:334–40. doi: 10.1016/j.ejmech.2016.12.058
55
PanTPengZTanLZouFZhouNLiuBet al. Nonsteroidal anti-inflammatory drugs potently inhibit the replication of zika viruses by inducing the degradation of AXL. J virology. (2018) 92(20):e01018-18. doi: 10.1128/JVI.01018-18
56
EspañoENamJHSongEJSongDLeeCKKimJK. Lipophilic statins inhibit zika virus production in vero cells. Sci Rep (2019) 9(1):1–1.
57
KimJASeongRKKumarMShinOS. Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models. Viruses (2018) 10(2):72. doi: 10.3390/v10020072
58
YangSXuMLeeEMGorshkovKShiryaevSAHeSet al. Emetine inhibits zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell discovery. (2018) 4(1):1–4. doi: 10.1038/s41421-018-0034-1
59
RosenBDinventorUS PHYTOTHERAPY Incassignee. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the ZIKA virus. United States patent US (2017) 9:675,582.
60
BatistaMNBragaACCamposGRSouzaMMMatosRPLopesTZet al. Natural products isolated from oriental medicinal herbs inactivate zika virus. Viruses (2019) 11(1):49. doi: 10.3390/v11010049
61
LaiZZHoYJLuJW. Cephalotaxine inhibits zika infection by impeding viral replication and stability. Biochem Biophys Res Commun (2020) 522(4):1052–8. doi: 10.1016/j.bbrc.2019.12.012
62
RoyALimLSrivastavaSLuYSongJ. Solution conformations of zika NS2B-NS3pro and its inhibition by natural products from edible plants. PloS One (2017) 12(7):e0180632. doi: 10.1371/journal.pone.0180632
63
RauschKHackettBAWeinbrenNLReederSMSadovskyYHunterCAet al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against zika virus. Cell Rep (2017) 18(3):804–15. doi: 10.1016/j.celrep.2016.12.068
64
XuMLeeEMWenZChengYHuangWKQianXet al. Identification of small-molecule inhibitors of zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med (2016) 22(10):1101–7. doi: 10.1038/nm.4184
65
LeonardiWZilbermintzLChengLWZozayaJTranSHElliottJHet al. Bithionol blocks pathogenicity of bacterial toxins, ricin and zika virus. Sci Rep (2016) 6(1):1–2. doi: 10.1038/srep34475
66
PuschnikASMarceauCDOoiYSMajzoubKRinisNContessaJNet al. A small-molecule oligosaccharyltransferase inhibitor with pan-flaviviral activity. Cell Rep (2017) 21(11):3032–9. doi: 10.1016/j.celrep.2017.11.054
67
de CarvalhoOVFélixDMde MendonçaLRde AraújoCMde Oliveira FrancaRFCordeiroMTet al. The thiopurine nucleoside analogue 6-methylmercaptopurine riboside (6MMPr) effectively blocks zika virus replication. Int J antimicrobial agents. (2017) 50(6):718–25. doi: 10.1016/j.ijantimicag.2017.08.016
68
GhezziSCooperLRubioAPaganiICapobianchiMRIppolitoGet al. Heparin prevents zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res (2017) 140:13–7. doi: 10.1016/j.antiviral.2016.12.023
69
CostaVVDel SartoJLRochaRFSilvaFRDoriaJGOlmoIGet al. N-methyl-d-aspartate (NMDA) receptor blockade prevents neuronal death induced by zika virus infection. MBio (2017) 8(2):e00350-17. doi: 10.1128/mBio.00350-17
70
RetallackHDi LulloEAriasCKnoppKALaurieMTSandoval-EspinosaCet al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci (2016) 113(50):14408–13.
71
LeiJVermillionMSJiaBXieHXieLMcLaneMWet al. IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following zika virus infection. JCI Insight (2019) 4(7):1–15. doi: 10.1172/jci.insight.122678
72
PattnaikASahooBRPattnaikAK. Current status of zika virus vaccines: successes and challenges. Vaccines (2020) 8(2):266. doi: 10.3390/vaccines8020266
73
GriffinBDMuthumaniKWarnerBMMajerAHaganMAudetJet al. DNA Vaccination protects mice against zika virus-induced damage to the testes. Nat Commun (2017) 8(1):1–8. doi: 10.1038/ncomms15743
74
WangRLiaoXFanDWangLSongJFengKet al. Maternal immunization with a DNA vaccine candidate elicits specific passive protection against post-natal zika virus infection in immunocompetent BALB/c mice. Vaccine (2018) 36(24):3522–32. doi: 10.1016/j.vaccine.2018.04.051
75
de La VegaMAPiretJGriffinBDRhéaumeCVenableMCCarbonneauJet al. Zika-induced male infertility in mice is potentially reversible and preventable by deoxyribonucleic acid immunization. J Infect diseases. (2019) 219(3):365–74. doi: 10.1093/infdis/jiy336
76
HraberPBradfuteSClarkeEYeCPitardB. Amphiphilic block copolymer delivery of a DNA vaccine against zika virus. Vaccine (2018) 36(46):6911–7. doi: 10.1016/j.vaccine.2018.10.022
77
Grubor-BaukBWijesundaraDKMasavuliMAbbinkPPetersonRLProwNAet al. NS1 DNA vaccination protects against zika infection through T cell–mediated immunity in immunocompetent mice. Sci advances. (2019) 5(12):eaax2388. doi: 10.1126/sciadv.aax2388
78
ToAMedinaLOMfuhKOLiebermanMMWongTANamekarMet al. Recombinant zika virus subunits are immunogenic and efficacious in mice. MSphere (2018) 3(1):e00576-17. doi: 10.1128/mSphere.00576-17
79
MedinaLOToALiebermanMMWongTANamekarMNakanoEet al. A recombinant subunit based zika virus vaccine is efficacious in non-human primates. Front Immunol (2018) 9:2464. doi: 10.3389/fimmu.2018.02464
80
YangMDentMLaiHSunHChenQ. Immunization of zika virus envelope protein domain III induces specific and neutralizing immune responses against zika virus. Vaccine (2017) 35(33):4287–94. doi: 10.1016/j.vaccine.2017.04.052
81
TaiWHeLWangYSunSZhaoGLuoCet al. Critical neutralizing fragment of zika virus EDIII elicits cross-neutralization and protection against divergent zika viruses. Emerging Microbes infections. (2018) 7(1):1–8. doi: 10.1038/s41426-017-0007-8
82
ZhuXLiCAfridiSKZuSXuJWQuanquinNet al. E90 subunit vaccine protects mice from zika virus infection and microcephaly. Acta neuropathologica Commun (2018) 6(1):1–2. doi: 10.1186/s40478-018-0572-7
83
ShanCMuruatoAEJaggerBWRichnerJNunesBTMedeirosDet al. A single-dose live-attenuated vaccine prevents zika virus pregnancy transmission and testis damage. Nat Commun (2017) 8(1):1–9. doi: 10.1038/s41467-017-00737-8
84
RichnerJMJaggerBWShanCFontesCRDowdKACaoBet al. Vaccine mediated protection against zika virus-induced congenital disease. Cell (2017) 170(2):273–83. doi: 10.1016/j.cell.2017.06.040
85
XieXKumDBXiaHLuoHShanCZouJet al. A single-dose live-attenuated zika virus vaccine with controlled infection rounds that protects against vertical transmission. Cell Host Microbe (2018) 24(4):487–99. doi: 10.1016/j.chom.2018.09.008
86
BullardBLCorderBNGormanMJDiamondMSWeaverEA. Efficacy of a T cell-biased adenovirus vector as a zika virus vaccine. Sci Rep (2018) 8(1):1–0. doi: 10.1038/s41598-018-35755-z
87
SteffenTHassertMHoftSGStoneETZhangJGeerlingEet al. Immunogenicity and efficacy of a recombinant human adenovirus type 5 vaccine against zika virus. Vaccines (2020) 8(2):170. doi: 10.3390/vaccines8020170
88
GuoQChanJFPoonVKWuSChanCCHouLet al. Immunization with a novel human type 5 adenovirus-vectored vaccine expressing the premembrane and envelope proteins of zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models. J Infect diseases. (2018) 218(3):365–77. doi: 10.1093/infdis/jiy187
89
López-CamachoCAbbinkPLaroccaRADejnirattisaiWBoydMBadamchi-ZadehAet al. Rational zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat Commun (2018) 9(1):1–1.
90
AbbinkPLaroccaRAde la BarreraRABricaultCAMoseleyETBoydMet al. Protective efficacy of multiple vaccine platforms against zika virus challenge in rhesus monkeys. Science (2016) 353(6304):1129–32. doi: 10.1126/science.aah6157
91
LiAYuJLuMMaYAttiaZShanCet al. A zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun (2018) 9(1):1–7. doi: 10.1038/s41467-018-05276-4
92
ShiXHuJGuoJWuCXiongSDongC. A vesicular stomatitis virus-based vaccine carrying zika virus capsid protein protects mice from viral infection. Virologica Sinica. (2019) 34(1):106–10. doi: 10.1007/s12250-019-00083-7
93
BaldwinWRLivengoodJAGieblerHAStovallJLBoroughsKLSonnbergSet al. Purified inactivated zika vaccine candidates afford protection against lethal challenge in mice. Sci Rep (2018) 8(1):1–3. doi: 10.1038/s41598-018-34735-7
94
LecouturierVPavotVBerryCDonadieuAde MontfortABoudetFet al. An optimized purified inactivated zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. NPJ Vaccines (2020) 5(1):1–0. doi: 10.1038/s41541-020-0167-8
95
YoungGBohningKJZahralban-SteeleMHatherGTadepalliSMickeyKet al. Complete protection in macaques conferred by purified inactivated zika vaccine: defining a correlate of protection. Sci Rep (2020) 10(1):1–9. doi: 10.1038/s41598-020-60415-6
96
AbbinkPLaroccaRAVisitsunthornKBoydMde la BarreraRAGromowskiGDet al. Durability and correlates of vaccine protection against zika virus in rhesus monkeys. Sci Trans Med (2017) 9(420):eaao4163. doi: 10.1126/scitranslmed.aao4163
97
EspinosaDMendyJManayaniDVangLWangCRichardTet al. Passive transfer of immune sera induced by a zika virus-like particle vaccine protects AG129 mice against lethal zika virus challenge. EBioMedicine (2018) 27:61–70. doi: 10.1016/j.ebiom.2017.12.010
98
DaiSZhangTZhangYWangHDengF. Zika virus baculovirus-expressed virus-like particles induce neutralizing antibodies in mice. Virologica Sinica. (2018) 33(3):213–26. doi: 10.1007/s12250-018-0030-5
99
YangMLaiHSunHChenQ. Virus-like particles that display zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci Rep (2017) 7(1):1–2. doi: 10.1038/s41598-017-08247-9
100
ZhongZPortela CataniJPMc CaffertySCouckLVan Den BroeckWGorléNet al. Immunogenicity and protection efficacy of a naked self-replicating mRNA-based zika virus vaccine. Vaccines (2019) 7(3):96 1–17. doi: 10.3390/vaccines7030096
101
RichnerJMHimansuSDowdKAButlerSLSalazarVFoxJMet al. Modified mRNA vaccines protect against zika virus infection. Cell (2017) 168(6):1114–25. doi: 10.1016/j.cell.2017.02.017
102
PardiNHoganMJPelcRSMuramatsuHAndersenHDeMasoCRet al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature (2017) 543(7644):248–51. doi: 10.1038/nature21428
103
MwalikoCNyaruabaRZhaoLAtoniEKarunguSMwauMet al. Zika virus pathogenesis and current therapeutic advances. Pathog Global Health (2021) 115(1):21–39. doi: 10.1080/20477724.2020.1845005
104
ZhouKLiCShiWHUXNandakumarKSJiangSZhangN. Current progress in the development of Zika virus vaccines. Vaccines (2021) 1004:1–17.
105
SharmaVSharmaMDhullDSharmaYKaushikSKaushikS. Zika virus: an emerging challenge to public health worldwide. Can J Microbiol (2020) 66(2):87–98. doi: 10.1139/cjm-2019-0331
106
PetersenLRJamiesonDJPowersAMHoneinMA. Zika virus. New Engl J Med (2016) 374(16):1552–63. doi: 10.1056/NEJMra1602113
107
World Health Organization. WHO guidelines for the prevention of sexual transmission of zika virus: Executive summary (No. WHO/RHR/19.4). (2019). World Health Organization. Available at: https://apps.who.int/iris/handle/10665/311026.
Summary
Keywords
transmission, vaccines, therapeutics, Zika (ZIKV), epidemiology
Citation
Dahiya N, Yadav M, Singh H, Jakhar R and Sehrawat N (2023) ZIKV: Epidemiology, infection mechanism and current therapeutics. Front. Trop. Dis 3:1059283. doi: 10.3389/fitd.2022.1059283
Received
01 October 2022
Accepted
07 December 2022
Published
23 January 2023
Volume
3 - 2022
Edited by
Bapi Pahar, Integrated Research Facility (NIH), United States
Reviewed by
Luis Del Carpio-Orantes, Delegación Veracruz Norte, Mexico; Ricardo Palacios, GlaxoSmithKline, Italy
Updates
Copyright
© 2023 Dahiya, Yadav, Singh, Jakhar and Sehrawat.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Neelam Sehrawat, neelamsehrawat@mdurohtak.ac.in
This article was submitted to Neglected Tropical Diseases, a section of the journal Frontiers in Tropical Diseases
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.